Stock MSB MESOBLAST LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Mesoblast Limited

Equities

MSB

AU000000MSB8

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:23 2024-05-23 am EDT 		5-day change 1st Jan Change
1.18 AUD +2.61% Intraday chart for Mesoblast Limited +12.38% +280.65%
Apr. 01 ADRs End Higher; Connect Biopharma Climbs 26% DJ
Mar. 28 ADRs End Lower; NuCana Slides 15% DJ

Business Summary

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Number of employees: 83

Sales per Business

AUD in Million2022Weight2023Weight Delta
Adult Stem Cell Technology
100.0 %
14 100.0 % 11 100.0 % -20.80%

Sales per region

AUD in Million2022Weight2023Weight Delta
Australia, United States and Singapore
100.0 %
14 100.0 % 11 100.0 % -20.80%

Managers

Managers TitleAgeSince
Silviu Itescu FOU
 Founder 67 04-06-07
Andrew Chaponnel DFI
 Director of Finance/CFO - 12-05-31
Dagmar Rosa-Bjorkeson COO
 Chief Operating Officer 60 20-07-23
Eric Rose CTO
 Chief Tech/Sci/R&D Officer 73 13-04-14
Paul Hughes IRC
 Investor Relations Contact - 19-01-31
Niva Sivakumar SEC
 Corporate Secretary - 13-12-31
Paul Simmons PRN
 Corporate Officer/Principal - 10-12-31
Geraldine Storton LAW
 General Counsel - 15-11-30
Peter Howard LAW
 General Counsel - 11-06-30
Michael Schuster PRN
 Corporate Officer/Principal - 03-12-31

Members of the board

Members of the board TitleAgeSince
Eric Rose CTO
 Chief Tech/Sci/R&D Officer 73 13-04-14
Joseph Swedish BRD
 Director/Board Member 72 18-06-17
William Burns BRD
 Director/Board Member 76 14-03-05
Philip Facchina BRD
 Director/Board Member 62 21-03-28
Silviu Itescu FOU
 Founder 67 04-06-07
Jane Bell CHM
 Chairman - 22-08-17
Philip Krause BRD
 Director/Board Member - 22-03-23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,015,342,237 874,737,926 ( 86.15 %) 542,903 ( 0.0535 %) 86.15 %

Shareholders

NameEquities%Valuation
Gregory George
14.61 %
166,849,364 14.61 % 107 M $
Silviu Itescu
6.915 %
78,958,928 6.915 % 51 M $
M&G Investment Management Ltd.
2.408 %
27,496,868 2.408 % 18 M $
Thorney Investment Group Australia Pty Ltd.
1.847 %
21,093,767 1.847 % 14 M $
Independent Asset Management Pty Ltd.
0.7007 %
8,000,400 0.7007 % 5 M $
DFA Australia Ltd.
0.4209 %
4,805,897 0.4209 % 3 M $
Novum Asset Management AG
0.4110 %
4,693,000 0.4110 % 3 M $
Gregory John Matthews
0.3548 %
4,051,124 0.3548 % 3 M $
Pension Reserves Investment Management Board
0.1841 %
2,102,165 0.1841 % 1 M $
Lalp Pty Ltd.
0.1521 %
1,737,223 0.1521 % 1 M $
NameEquities%Valuation
Group One Trading LP
0.1258 %
143,671 0.1258 % 883 577 $
Summit X LLC
0.1224 %
139,752 0.1224 % 859 475 $
Penbrook Management LLC
0.1096 %
125,175 0.1096 % 769 826 $
REGAL PARTNERS LIMITED
0.1027 %
117,243 0.1027 % 721 044 $
Prosperity Wealth Management, Inc.
0.0677 %
77,350 0.0677 % 475 703 $
Morgan Stanley Capital Services LLC
0.0603 %
68,902 0.0603 % 423 747 $
Chase Investment Counsel Corp.
0.0522 %
59,600 0.0522 % 366 540 $
Wells Fargo Advisors Financial Network LLC
0.0519 %
59,214 0.0519 % 364 166 $
HRT Financial LLC
0.0506 %
57,815 0.0506 % 355 562 $
Susquehanna Securities LLC
0.0504 %
57,506 0.0504 % 353 662 $

Company contact information

Mesoblast Ltd.

55 Collins Street Level 38

3000, Melbourne

+61 3 9639 6036

http://www.mesoblast.com
address Mesoblast Limited(MSB)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Mesoblast Limited

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.15 AUD
Average target price
1.1 AUD
Spread / Average Target
-4.35%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MESOBLAST LIMITED Stock Mesoblast Limited
+280.65% 871M
MODERNA, INC. Stock Moderna, Inc.
+64.66% 62.59B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.28% 41.18B
LONZA GROUP AG Stock Lonza Group AG
+44.76% 40.29B
CELLTRION, INC. Stock Celltrion, Inc.
-8.29% 27.9B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.06% 26.21B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.55% 19.09B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+5.56% 13.08B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.31% 12.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.40% 12.05B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MSB Stock
  4. Company Mesoblast Limited